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MALARIA
A genetic intervention
A tool that analyzes the genome of parasites found in the blood of
malaria patients can help inform policy decisions on how best to tackle
the rise in drug-resistant infections.
COLIN SUTHERLAND AND DIDIER MENARD
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alaria cases may have decreased over
the last 15 years, but the number of
parasites resistant to treatment is ris-
ing, particularly in Southeast Asia. Indeed, some
Plasmodium falciparum parasites (which cause
the most severe form of the disease) no longer
respond to the most widely used antimalarial
drugs (Blasco et al., 2017; Menard and Don-
dorp, 2017). This includes artemisinin-based
combination therapy (ACT), the first line of
defense recommended by National Malaria Con-
trol Programs (Noedl et al., 2008;
Dondorp et al., 2009; Cheeseman et al., 2012;
Ariey et al., 2014; Takala-Harrison et al., 2015;
Amato et al., 2018; Hamilton et al., 2019;
Imwong et al., 2020; Stokes et al., 2021). The
reduced susceptibility to artemisinin and its part-
ner drugs has resulted in ACT therapy failing to
treat over 50% of malaria cases in some regions
of Cambodia, Thailand and Vietnam (van der
Pluijm et al., 2020; van der Pluijm et al., 2019).
In order to make rapid, effective decisions on
how best to tackle this rise in resistance, policy-
makers need to be aware of which strains are
present in different regions. However, clinical
studies of malaria are logistically difficult and
expensive to implement. An alternative
approach is to study molecular markers in the
blood of malaria patients, which can also pro-
vide an earlier indication of where resistant para-
sites have emerged (World Health
Organization, 2020). Now, in eLife, Olivo
Miotto and colleagues – including Christopher
Jacob (Wellcome Sanger Institute) as first author
– report a new genetic surveillance platform
called ‘GenRe-Mekong’ which monitors the
spread of resistant parasites in the Greater
Mekong Subregion (Jacob et al., 2021).
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Jacob et al. collaborated with various
National Malaria Control Programs and scientific
partners to collect 9,623 blood samples from
patients diagnosed with P. falciparum malaria in
eight countries (Vietnam, Laos, Cambodia, Thai-
land, Myanmar, Bangladesh, India and Demo-
cratic Republic of Congo). A cutting-edge
sequencing technology was then applied to
extract and amplify specific genes from the para-
sitic genome. Jacob et al. analyzed this genetic
data for variants which are known to reduce par-
asites’ susceptibility to the most widely used
treatments, including artemisinin (Figure 1).
Based on the proportion of variants present in
each gene, each sample was then classified as
having a ‘sensitive’, ‘resistant’ or ‘undetermined’
response to an antimalarial drug.
Data from the genetic surveillance platform
were delivered to National Malaria Control Pro-
grams as maps which simply describe how the
presence and absence of resistant parasites is
changing over time. Notably, the team (who are
based in the United States, United Kingdom,
Vietnam, Laos, Cambodia, Thailand, Bangladesh,
Switzerland, Democratic Republic of Congo,
France, Myanmar and India) provided concrete
examples of how this information can be
translated into policy decisions. For example,
the database found that parasites less suscepti-
ble to artemisinin and one of its partner drugs
(originally identified in Cambodia and Thailand)
had spread to southern provinces in Vietnam
and Laos which were previously unaffected by
these resistant strains. This led National Malaria
Control Programs in these regions to reassess
which frontline therapies to use and where to
allocate resources to help combat the rise in
drug resistance.
Beyond providing actionable information on
the spread of resistance, the approach could
also shed light on the complexity of infection,
revealing whether a patient was carrying differ-
ent species or strains of parasites at the same
time. It could also be used to infer where the
strains detected originated, which could help to
reconstruct how parasites resistant to multiple
drugs spread to different regions.
Although this platform could rapidly
become an essential, complementary
strategy for eliminating malaria, additional work
is needed to overcome some drawbacks. First,
the changes in drug susceptibility caused by the
genetic variants is not directly tested, but
assumed on the basis of earlier research
Figure 1. Bridging the gap between research and malaria surveillance in the Greater Mekong Subregion.
Previous research studying the genome of parasites has led to the identification of genetic variants which reduce
parasites’ susceptibility to antimalarial drugs (blue box, left). Jacob et al. used this data to create a genetic
surveillance platform called GenRe-Mekong, which analyzes the blood samples of malaria patients for these
genetic variants (green box, right). Data from this platform is then regularly shared with local research
organizations and various National Malaria Control Programs (NMCPs) in the Greater Mekong Subregion, who can
use this information to help inform their policy decisions for tackling drug-resistant infections.
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(Figure 1). Second, the platform will be unable
to capture new resistant strains, unless newly
discovered variants are continuously added to
the GenRe-Mekong database. Last, the current
approach is unlikely to be applicable to coun-
tries in the African continent. This is because
patients are often infected by multiple strains of
P. falciparum at the same time, which makes it
difficult to apply the method across many variant
genes and classify the resistance profile. Never-
theless, the work by Jacob et al. demonstrates
how genetic data can be a tremendously practi-
cal tool that can help policy makers rapidly
adapt their treatment strategies in response to
rising levels of drug resistance.
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